Abstract
Background
Clozapine is the most effective medication for the positive symptoms of treatment-refractory schizophrenia. Although clozapine use is associated with fewer admissions, less is known about the impact of clozapine cessation on hospitalisation.
Aims
The aims of this study were to investigate whether clozapine-reduced psychiatric inpatient admissions and bed days, and investigate patient factors associated with these changes from a sample of 1906 people commenced on clozapine.
Methods
All people commencing clozapine during an acute hospitalisation over a 10-year period in Queensland, Australia, were included in this retrospective cohort study. A mirror image design was used to compare psychiatric bed days and hospitalisations 2 years before and after clozapine treatment, and the impact of clozapine continuation or early cessation. Changes in psychiatric bed days and hospitalisations were analysed using linear regression, adjusting for the duration on clozapine, sex, age, indigenous status, country of origin and time to clozapine commencement.
Results/outcomes
There was a significant reduction in bed days (29.55 days vs 24.46 days, p < 0.001) and admissions (2.27 vs 1.87 < 0.001) associated with clozapine commencement. This remained significant among clozapine continuers, but not among those with early cessation. Longer duration on clozapine was associated with greater reductions in psychiatric bed days and admissions. Age, sex and time to clozapine commencement, indigeneity and country of origin did not impact outcomes.
Conclusion/interpretation
Longer clozapine therapy led to a greater reduction in psychiatric bed days and hospitalisations. Early cessation was associated with a return to pre-clozapine levels of bed days and admissions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bachmann C, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, Coma Fusté A, Furu K, Garuoliené K, Hoffmann F (2017) International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand 136:37–51
Bhavsar V, Kosidou K, Orsini N, Widman L, Maccabe J, Dalman C (2018) Could clozapine reduce violent offending? Schizophr Bull 44:S67
Forrester T, Siskind D, Winckel K, Wheeler A, Hollingworth S (2015) Increasing clozapine dispensing trends in Queensland, Australia 2004–2013. Pharmacopsychiatry 48:164–169
Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, Mcgorry P, Nielssen O, Tran N (2016) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 50:410–472
Gee SH, Shergill SS, Taylor DM (2016) Factors associated with changes in hospitalisation in patients prescribed clozapine. J Psychopharmacol 30:819–825
Howes OD, Mccutcheon R, Agid O, De Bartolomeis A, Van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran F, Glenthoj BY, Graff-Guerrero A, Hallak JE, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J, Leweke FM, Maccabe JH, Mcnabb CB, Meltzer H, Moller HJ, Nakajima S, Pantelis C, Reis Marques T, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Ucok A, Umbricht D, Walters JT, Kane J, Correll CU (2017) Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 174:216–229
Knapp M, Mangalore R, Simon J (2004) The global costs of schizophrenia. Schizophr Bull 30:279–293
Land R, Siskind D, Mcardle P, Kisely S, Winckel K, Hollingworth SA (2017) The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand 135:296–309
Legge SE, Hamshere M, Hayes RD, Downs J, O'Donovan MC, Owen MJ, Walters JT, Maccabe JH (2016) Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophr Res 174:113–119
Robinson G, Kisely S, Siskind D, Flanagan RJ, Wheeler AJ (2017) Echocardiography and clozapine: is current clinical practice inhibiting use of a potentially life-transforming therapy? Aust Fam Physician 46:169
Saha S, Chant D, Welham J, Mcgrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2:413–433
Siskind D, Mccartney L, Goldschlager R, Kisely S (2016) Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 209:385–392
Stone-Brown K, Naji M, Francioni A, Myers K, Samarendra H, Mushtaq-Chaudhry H, Heslop S, Sengupta S, Ross CC, Larkin F, Das M (2016) Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital. CNS Spectr 21:60–69
Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374:620–627
Ucok A, Polat A, Cakir S, Genc A (2006) One year outcome in first episode schizophrenia. Predictors of relapse. Eur Arch Psychiatry Clin Neurosci 256:37–43
Verdoux H, Quiles C, Bachmann CJ, Siskind D (2018) Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. Schizophr Res 201:10–19
Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2007) Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335:806–808
Wimberley T, Maccabe JH, Laursen TM, Sørensen HJ, Astrup A, Horsdal HT, GASSE C, STØVRING H (2017) Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatr 174:990–998
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval was granted by the Metro South Human Research Ethics Committee HREC/15/QPAH/400.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 16.9 kb)
Rights and permissions
About this article
Cite this article
Siskind, D., Reddel, T., MacCabe, J.H. et al. The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study. Psychopharmacology 236, 1931–1935 (2019). https://doi.org/10.1007/s00213-019-5179-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-019-5179-6